FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

Gottlieb Worried About RFK Jr. Pick for HHS

Former FDA Commissioner Scott Gottlieb predicts a difficult path for Robert F. Kennedy Jr. to win Senate confirmation as HHS secretary due to his extr...

latest-news-card-1
Human Drugs

J&J Seeks Tremfya Approval for Pediatric Uses

Johnson & Johnson files two supplemental BLAs for Tremfya (guselkumab) for treating certain children with moderate-to-severe plaque psoriasis and acti...

latest-news-card-1
Human Drugs

Applied Therapeutics NDA Denied Approval

FDA issues Applied Therapeutics a complete response letter on its NDA for govorestat and its use for treating classic galactosemia.

latest-news-card-1
Medical Devices

FDA OKs Mentor's Larger Breast Implants

FDA approves a Mentor Worldwide PMA for its MemoryGel Enhance Breast Implants for reconstruction breast surgery in post-mastectomy women.

latest-news-card-1
Human Drugs

Circulating Tumor DNA Use Guidance

FDA publishes a guidance to help sponsors planning to use circulating tumor DNA as a biomarker in some cancer trials.

latest-news-card-1
Human Drugs

Patheon Italia FDA-483 Out

FDA releases the form FDA-483 with four observations from a 2023 inspection at the Monza, Italy-based Patheon Italia sterile drug manufacturer.

latest-news-card-1
Federal Register

Follow-up Testing for Ames-Positive Drugs Guide

Federal Register notice: FDA makes available a draft guidance entitled Recommended Follow-up Testing for an Ames-Positive Drug (Active Ingredient) or ...

latest-news-card-1
Federal Register

Guide on Assessing Ovarian Toxicity

Federal Register notice: FDA makes available a draft guidance entitled Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development ...

latest-news-card-1
Federal Register

Oncologic Drugs Advisory Committee Renewal

Federal Register notice: FDA renews its Oncologic Drugs Advisory Committee for an additional two years.

latest-news-card-1
Human Drugs

8 GDUFA Science and Research Priorities

FDA identifies eight broad areas for the GDUFA FY 2025 science and research priorities.